Randomised controlled trials, including the National Lung Screening Trial (NLST) and the
NELSON trial, have shown reduced mortality with lung cancer screening with low-dose CT …

In the past decade, the introduction of molecularly targeted agents and immune-checkpoint
inhibitors has led to improved survival outcomes for patients with advanced-stage lung …

Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for
cancer detection and intervention. Here, we use a machine learning model for detecting …

The present review is an update of the research and development efforts regarding the use
of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical …

Lung cancer remains the leading cause of cancer related deaths worldwide. Lung cancer
screening using low-dose computed tomography (LDCT) has been shown to reduce lung …

Background Lung cancer screening with low-dose chest CT (LDCT) reduces the mortality of
eligible individuals. Blood signatures might act as a standalone screening tool, refine the …

PURPOSE To investigate whether a panel of circulating protein biomarkers would improve
risk assessment for lung cancer screening in combination with a risk model on the basis of …

Background Individual plasma proteins have been identified as minimally invasive
biomarkers for lung cancer diagnosis with potential utility in early detection. Plasma …

Solid cancers are one of the leading causes of cancer related deaths, characterized by rapid
growth of tumour, and local and distant metastases. Current advances on multimodality care …

The therapeutics based on nanoparticles (NPs) are considered as the promising strategy for
tumor detection and treatment. However, one of the most challenges is the adsorption of …